Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVAC-M
- Development stage
- Preclinical
- Lead developer
- Cellid
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
BVAC-M is a preclinical-stage therapeutic cancer vaccine being developed by Cellid for the treatment of melanoma. It is built on the company's proprietary CeliVax platform, which utilizes autologous B cells and monocytes as antigen-presenting cells. The vaccine is engineered to target two specific tumor-associated antigens: GP100 (Melanocyte protein PMEL) and MAGE-A3 (Melanoma-associated antigen 3). By presenting these antigens, BVAC-M aims to stimulate a robust T-cell and Natural Killer (NK) cell immune response against melanoma cells.
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on BVAC-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVAC-M.